Compare CTKB & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTKB | NKX |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.3M | 666.9M |
| IPO Year | 2021 | N/A |
| Metric | CTKB | NKX |
|---|---|---|
| Price | $4.67 | $12.13 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.63 | N/A |
| AVG Volume (30 Days) | ★ 548.8K | 220.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,015,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $2.37 | $11.45 |
| 52 Week High | $6.18 | $13.20 |
| Indicator | CTKB | NKX |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 43.26 |
| Support Level | $4.56 | $11.67 |
| Resistance Level | $4.85 | $12.99 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 69.70 | 80.70 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.